CLBT

Cellebrite DI Ltd. (CLBT) investors absorbed losses when shares sold off after the Company reported Q2 2026 revenue of roughly $131.1 million and reduced its full-year 2026 ARR and revenue targets -- Levi & Korsinsky is investigating the loss impact to shareholders. Cellebrite DI Ltd. (CLBT) investors absorbed losses when shares sold off after the Company reported Q2 2026 revenue of roughly $131.1 million and reduced its full-year 2026 ARR and revenue targets -- Levi & Korsinsky is investigating the loss impact to shareholders.

New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ: CLBT).

Boston, Massachusetts--(Newsfile Corp. - August 17, 2026) - Block & Leviton is investigating Cellebrite DI (NASDAQ: CLBT) for potential securities law violations. Investors who have lost money in their Cellebrite DI investment should contact the firm to learn more about how they might recover those losses.

Cellebrite DI Ltd. (CLBT) shareholders lost money when the stock sold off more than 30% following the Company's Q2 2026 results -- Levi & Korsinsky is investigating the Company's disclosures concerning their previous projections and related discussions.

Cellebrite DI Ltd. (CLBT) Q2 2026 Earnings Call Transcript

MILWAUKEE, Aug. 13, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Cellebrite (NASDAQ: CLBT). The investigation results from inaccurate statements Cellebrite may have made regarding its financial statements, business operations and prospects.

Boston, Massachusetts--(Newsfile Corp. - August 13, 2026) - Block & Leviton is investigating Cellebrite DI (NASDAQ: CLBT) for potential securities law violations. Investors who have lost money in their Cellebrite DI investment should contact the firm to learn more about how they might recover those losses.

Cellebrite DI NASDAQ: CLBT reported second-quarter results that fell short of its expectations for annual recurring revenue, citing delayed large transactions, slower-than-anticipated pricing and expansion gains from customer migrations, and added procurement requirements for cloud and artificial intelligence offerings. The company lowered its full-year ARR and revenue outlook while raising its adjusted EBITDA target.

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12 per share.

Company Reports Second-Quarter 2026 Results ; Company Lowers Full-Year 2026 ARR and Revenue Outlook and Raises Adjusted EBITDA Target TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 13, 2026 /PRNewswire/ -- Cellebrite DI Ltd.